agsandrew-shutterstock-com-1

agsandrew / Shutterstock.com

9 April 2015Genetics

The CRISPR patent war

Research into genome-editing technologies has progressed to a point where we can read the strains of DNA that exist in almost every cell of our bodies as if they were on a word processor and take faulty, disease-causing genes out of a sequence and replace them with functioning ones.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Why CRISPR may define pre- and post-AIA changes

17 September 2015 Many players are piling into the scrum surrounding the patent eligibility of CRISPR technology. Mercedes Meyer of Drinker Biddle & Reath discusses the legal implications of CRISPR as a potential groundbreaking foundation technology.

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

More on this story

Why CRISPR may define pre- and post-AIA changes

17 September 2015 Many players are piling into the scrum surrounding the patent eligibility of CRISPR technology. Mercedes Meyer of Drinker Biddle & Reath discusses the legal implications of CRISPR as a potential groundbreaking foundation technology.

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

More on this story

Why CRISPR may define pre- and post-AIA changes

17 September 2015 Many players are piling into the scrum surrounding the patent eligibility of CRISPR technology. Mercedes Meyer of Drinker Biddle & Reath discusses the legal implications of CRISPR as a potential groundbreaking foundation technology.

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

More features

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

UKIPO launches ‘revolutionary’ patent filing and AI tool

BlueAllele says rival gained $100m from Regeneron deal using patented tech

Report reveals boom in digital health patents

Unified Patent Court: The cases, the numbers and what the future holds

Second chances: Brazil’s bid to revitalise the country’s healthcare system

Why the US non-competes ban has riled Big Pharma

Life sciences cases at the UPC will surely rise, but is the court prepared?